Measuring What Matters: Evidence and End Points That Define Disability in MS

Measuring What Matters: Evidence and End Points That Define Disability in MS

Panelists discuss how robust clinical evidence from major studies like the EPIC and OPERA trials demonstrates that progression independent of relapse activity (PIRA) is the primary driver of confirmed disability progression in patients with multiple sclerosis (MS), with clinical parameters over 3 to 6 months being the most meaningful measures of treatment impact.

Multiple sclerosis market expected to reach $25.9bn across the 7MM by 2034

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is poised to grow at a compound annual growth rate of 1.7% from $22.0bn in 2024 to $25.9bn in 2034, according to leading data and analytics company GlobalData’s recently published report, Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis.The post Multiple sclerosis mark…

Diagnosed prevalent cases of multiple sclerosis to increase by 0.19% AGR in 7MM during 2024-34, forecasts GlobalData - GlobalData

The diagnosed prevalent cases of multiple sclerosis (MS) in the seven major markets (7MM*) are projected to increase from 1.61 million in 2024 to 1.64 million in 2034 at an annual growth rate (AGR) of negative 0.19%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Multiple Sclerosis Epidemiology Analysis and Forecast to 2034,” reveals that in 2034, the US is forecasted to experience the greatest number of…